专利检索 ap:("ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.") AND inv:"Christopher PETERSEN" 第 1 页

1.

发明申请
DNMT3A KNOCK-OUT STAT5 ACTIVATED GENETICALLY ENGINEERED T-CELLS 有权

公开(公告)号：US20220226379A1

公开(公告)日：2022-07-21

申请号：US17602524

申请日：2020-04-08

申请人： ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.

发明人： Stephen GOTTSCHALK , Giedre KRENCIUTE , Christopher PETERSEN , Benjamin YOUNGBLOOD

IPC分类号： A61K35/17 , A61P35/02 , A61K35/545 , C12N9/10

摘要： The application provides modified immune effector cells wherein the DNA (cytosine-5)-methyltransferase 3A (DNMT3A)-mediated de novo DNA methylation of the cell genome is inhibited, and STAT5 signaling pathway is activated. The application also provides related pharmaceutical compositions and the methods for generating such modified immune effector cells. The application further provides uses of such modified immune effector cells for treating diseases such as cancers, infectious diseases and autoimmune diseases.

2.

发明申请
T CELL GENE EXPRESSION ANALYSIS FOR USE IN T CELL THERAPIES 有权

公开(公告)号：US20220326216A1

公开(公告)日：2022-10-13

申请号：US17608079

申请日：2020-04-08

申请人： ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.

发明人： Benjamin YOUNGBLOOD , Jeremy CRAWFORD , Yiping FAN , Caitlin ZEBLEY , Stephen GOTTSCHALK , Giedre KRENCIUTE , Christopher PETERSEN

IPC分类号： G01N33/50 , C07K14/705 , A61K35/17

摘要： The application provides T cell gene expression signatures that can be used to predict T cell therapy outcomes.